ZJYLNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends September 30
Jin Medical International Ltd.
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Feb 10, 2026
$2.11+0.03 (+1.44%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 10.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
29.2%
Operating margin
2.9%
Net margin
5.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -12.0% | +2.5% | – | – | |
| Gross profit | -36.4% | -0.8% | – | – | |
| Operating income | -83.3% | -34.2% | – | – | |
| Net income | -67.6% | -23.9% | – | – | |
| EPS, diluted | -50.0% | -20.6% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 4.1% | |
| Return on assets | – | – | 2.4% | |
| Current ratio | – | – | 1.86 | |
| Inventory turnover | – | – | 2.9× | |
| Capex to revenue | – | – | 32.0% | |
| Diluted shares | – | – | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Jin Medical International generated $14.64M from operations and spent $6.97M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$14.64M
Used
$6.97M
Capital expenditure$6.97M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin5.8%
×Asset turnover0.42×
×Equity multiplier1.70×
=Return on equity, FY20254.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 5.8% | 0.42× | 1.70× | 4.1% |
| FY2024 | 15.6% | 0.60× | 1.49× | 13.9% |
| FY2023 | 14.5% | 0.74× | 1.37× | 14.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$1.19M
- Cash generatingOperating cash flow above zero$2.90M
- Return on assets improvedROA up on the prior year11.2% → 2.6%
- Earnings backed by cashOperating cash flow above net income$2.90M vs $1.19M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.50 → 1.86
- No dilutionShare count did not rise8M → 8M
- Gross margin improvedGross margin up on the prior year40.43% → 29.22%
- More efficientAsset turnover rose0.71 → 0.45